Immunomedics to Present Updated Clinical Results With

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Immunomedics to Present Updated Clinical Results With Solid-Tumor Antibody-Drug Conjugates at Upcoming Conferences

MORRIS PLAINS, N.J., Oct. 22, 2014 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq: IMMU ) today announced that Dr. David M. Goldenberg, Chairman, Chief Scientific Officer, and Chief Medical Officer, will present updated results from Phase 2 clinical trials of the Company's two solid-tumor antibody-drug conjugates (ADCs), isactuzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), at two upcoming conferences.

At the 5 th Annual World ADC Summit in San Diego, CA, Dr. Goldenberg will report "Clinical Performance of Moderately-Toxic ADCs Demonstrates Improved Therapeutic Index in Patients with Diverse Metastatic Solid Cancers," in the session on "Early Clinical Development Strategies to Demonstrate Patient Benefit," at 12:00 p.m., Pacific Time, Wednesday, October 29, 2014.

In addition, Dr. Goldenberg will give an invited lecture on "Challenging the dogmas: Clinical efficacy of SN38 conjugated antibodies in solid tumours," at the 2014 Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, hosted by the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI), and the American Association for Cancer Research (AACR). The oral presentation is scheduled in the "Antibody-Based Therapies (ADC and others)" Plenary Session at 8:20 a.m., Central European Time, Thursday, November 20, 2014.

Cynthia L. Sullivan, President and Chief Executive Officer, commented: "Our founder and chief scientist, Dr. Goldenberg, was invited to present important new Phase 2 trial results with these novel antibody-drug conjugates because our platform technology departs from traditional ADCs by having a high ratio of a moderately cytotoxic drug, SN-38, conjugated to 2 different antibodies that together target most solid cancers. He will report the high therapeutic index of these agents, which is the ability to specifically deliver high and repeated doses with manageable toxicities (mostly neutropenia) in heavily-pretreated patients with metastatic cancers."

"We believe our ADC platform may represent a paradigm change in this technology, and we are eager to share these encouraging results in very difficult-to-treat cancers. Together, almost 200 patients have been studied with these two agents," she added.

About Immunomedics

Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Immunomedics' advanced proprietary technologies allow the Company to create humanized antibodies that can be used either alone in unlabeled or "naked" form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. Using these technologies, Immunomedics has built a pipeline of nine clinical-stage product candidates. Immunomedics has an ongoing collaboration with UCB, S.A. (UCB), to whom the Company licensed epratuzumab for the treatment of all non-cancer indications worldwide. UCB expects Phase 3 data in systemic lupus erythematosus in the first half of 2015. Immunomedics is exploring epratuzumab in oncology in collaboration with independent cancer study groups. Immunomedics' most advanced candidate to which it retains worldwide rights for all indications is 90 Y-clivatuzumab tetraxetan. The Company initiated a Phase 3 registration trial in January 2014 in patients with advanced pancreatic cancer and expects topline data in mid-2016. Immunomedics' portfolio of wholly owned product candidates also includes antibody-drug conjugates (ADCs) that are designed to deliver a specific payload of a chemotherapeutic directly to the tumor while reducing overall toxic effects that are usually found with conventional administration of these chemotherapeutic agents. Immunomedics' most advanced ADCs are IMMU-132 and IMMU-130, which are in Phase 2 trials for a number of solid tumors and metastatic colorectal cancer, respectively. Immunomedics also has a number of other product candidates that target solid tumors and hematologic malignancies, as well as other diseases, in various stages of clinical and pre-clinical development. These include bispecific antibodies targeting cancers and infectious diseases as T-cell redirecting immunotherapies, as well as bispecific antibodies for next-generation cancer and autoimmune disease therapies, created using its patented DOCK-AND-LOCK ® protein conjugation technology. The Company believes that its portfolio of intellectual property, which includes approximately 258 active patents in the United States and more than 400 foreign patents, protects its product candidates and technologies. Immunomedics' strength in intellectual property has resulted in a top-8 ranking in the Biotechnology industry by the Patent Board for the 2014 fiscal year. For additional information on the Company, please visit its website at www.immunomedics.com . The information on its website does not, however, form a part of this press release.

This release, in addition to historical information, may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials (including the funding therefor, outcomes, timing or associated costs), out-licensing arrangements (including the timing and amount of contingent payments), forecasts of future operating results, potential collaborations, and capital raising activities, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, new product development (including clinical trials outcome and regulatory requirements/actions), our dependence on UCB for the further development of epratuzumab for non-cancer indications, risks associated with the outcome of pending litigation, competitive risks to marketed products and availability of required financing and other sources of funds on acceptable terms, if at all, as well as the risks discussed in the Company's filings with the Securities and Exchange Commission. The Company is not under any obligation, and the Company expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

For More Information: Dr. Chau Cheng Senior Director, Investor Relations & Grant Management (973) 605-8200, extension 123

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Qonto's Banking License Raises the Stakes in Europe

Updated Category News Views 46

A regulatory stamp can look dull on paper, yet this one changes the machinery underneath Qonto. The Paris-based finance platform has received a Credit Institution license from France's ACPR and the European Central Bank, giving it a route to offer broader lending and savings products directly to small and midsize businesses across Europe. That is a serious corporate...

Continue Reading
LifeVac's 7,000 Reported Saves Deserve Careful Context

Updated Category News Views 138

Veggie straws are supposed to be harmless until they are not. LifeVac says a 19-month-old girl in South Dakota became unable to breathe on November 14 after eating the snack, with a sticky piece creating a complete airway obstruction. Her father retrieved the family's LifeVac, used the pediatric mask while she was on her back, and the company says one application...

Continue Reading
Aurora Innovation Faces Legal Probe After Stock Plunge

Updated Category News Views 136

Aurora's Troubles Draw Legal Scrutiny Looks like Aurora Innovation’s in the hot seat again, and not in a good way. When you see Kessler Topaz Meltzer & Check, LLP throwing their name into the mix, you know it’s getting serious. This legal eagle firm is poking around, seeing if Aurora stepped over the line with investors after their latest stumble—a production delay...

Continue Reading
Navan’s Travel Survey Sells Friction as a Business Case

Updated Category News Views 154

A forgotten charger can turn a routine trip into a small mutiny. That is the useful little truth sitting underneath Navan’s new survey of 2,000 Americans who travel for leisure or business. The company is poking at the annoyances people carry from the bedroom packing pile to the jet bridge: forgotten items, rushed airport arrivals, pre-flight drinks, chatty strangers,...

Continue Reading
Bank of America AML Claims Put Controls Under Fire

Updated Category News Views 157

A $1.2 billion compliance bill has a way of making investors stop pretending controls are boring. Moore Law PLLC is urging Bank of America shareholders to contact the firm over allegations tied to the bank's anti-money-laundering and Bank Secrecy Act systems. The notice follows what it describes as landmark October 13, 2026 enforcement actions by the Treasury Department's...

Continue Reading
Animal Parasite Market Growth Has a Resistance Catch

Updated Category News Views 156

Flea collars and cattle worms do not sound glamorous, yet this is exactly where durable animal-health revenue gets built. Wissen Research puts the global animal parasiticides market at $13.6 billion in 2026 and projects $18.6 billion by 2031, a 6.5% compound annual growth rate. That is respectable, not moonshot stuff, and frankly that is part of the appeal. Pet owners...

Continue Reading
Madrigal Pharmaceuticals Faces Legal Scrutiny Over Data

Updated Category News Views 152

Legal Storm Brews for Madrigal Pharmaceuticals Watch out, here comes another storm for Madrigal Pharmaceuticals, folks. This ain't no small drizzle either; it's a full-on legal monsoon, and it's soaked straight through the walls of their executive suite. We're talking a whistleblower sending alarm bells ringing about data fudging and some dodgy boardroom maneuvers—as if...

Continue Reading
Red Cat Stock Drama: Revenue Targets and Legal Waves

Updated Category News Views 123

Red Cat's Revenue Predictions Crash and Burn Sitting there on August 6, 2026, Red Cat Holdings had everyone believing they were on a fast track to hitting a hefty revenue target: $150–$180 million for FY2026. CEO Jeffrey Thompson didn't mince words, boasting confidence like a captain before a storm. Fast forward three months, and they're waving the white flag, tossing...

Continue Reading
FULC, DSGR and OPCH Deals Draw Fresh Shareholder Scrutiny

Updated Category News Views 85

Three proposed transactions have drawn the kind of legal glare that makes shareholders sit up and check the fine print twice. On November 18, 2026, Halper Sadeh LLC said it was investigating deals involving Fulcrum Therapeutics, Distribution Solutions Group, and Option Care Health for possible federal securities-law violations or fiduciary-duty breaches. That is not a...

Continue Reading
BNY's December Conference Slot Merits a Careful Listen

Updated Category News Views 118

A 10:40 a.m. conference appearance can look like wallpaper on a market calendar, but BNY's scheduled December 9 discussion deserves more attention than that. Robin Vince, the chief executive, is set to speak at the Goldman Sachs Financial Services Conference in New York, and the company has plainly warned that the conversation may include forward-looking statements and...

Continue Reading

Top 5 Most Recently Viewed Articles

Strategic Changes Ahead for Southwest Airlines Amid Challenges

Updated Category News Views 299

Southwest Airlines Faces Important Decisions for Recovery Southwest Airlines (NYSE: LUV) is preparing for critical decisions that will significantly impact its workforce, as the airline launches a key strategy to regain profitability. This move comes as pressures from activist investor Elliott Investment Management increase, highlighting a crucial moment for the company....

Continue Reading
Tetragon Financial Group: Insights from the 2024 Annual Report

Updated Category News Views 209

Tetragon Financial Group Limited Releases 2024 Annual Report Tetragon Financial Group Limited has recently published its 2024 Annual Report, a document that offers valuable insights into the organization’s performance and future direction. Investors can look forward to a detailed overview of the company’s accomplishments and strategic initiatives outlined in this...

Continue Reading
Hollyland Launches Affordable Lyra 4K Webcam with Pro Features

Updated Category News Views 189

Introducing the Hollyland Lyra 4K UHD Webcam Hollyland has launched an exciting new product in the world of online communication—the Lyra 4K UHD Webcam. Set to redefine entry-level webcams, this innovative device offers professional audio-visual capabilities without breaking the bank. Perfect for anyone from content creators to educators and remote workers, the Lyra...

Continue Reading
PEAK® Enhances Lineup with Innovative Antifreeze Solutions

Updated Category News Views 224

PEAK® Expands Product Offerings with Innovative Antifreeze Options PEAK's recent product refresh provides consumers with enhanced choices for antifreeze and coolant applications tailored to their vehicle needs. The company continually strives to innovate and lead in the automotive fluids sector. New Additions to PEAK® Product Line Old World Industries has unveiled...

Continue Reading
Transforming Backyards with Synthetic Grass: A Modern Solution

Updated Category News Views 127

Introducing the Benefits of Synthetic Grass For homeowners, particularly in busy urban areas, achieving a beautiful lawn can often feel like an uphill battle. The constant need for watering, mowing, and maintenance for natural grass, especially when pets are involved, can be daunting. This is where synthetic grass emerges as a revolutionary alternative, providing a...

Continue Reading